NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free MRKR Stock Alerts $4.22 +0.02 (+0.48%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$4.15▼$4.5050-Day Range$3.63▼$4.9152-Week Range$1.16▼$9.68Volume13,189 shsAverage Volume14,882 shsMarket Capitalization$37.60 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Marker Therapeutics alerts: Email Address Marker Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside160.7% Upside$11.00 Price TargetShort InterestHealthy1.00% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.14Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.10 out of 5 starsMedical Sector159th out of 904 stocksPharmaceutical Preparations Industry59th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingMarker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMarker Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.00% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 40.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marker Therapeutics is -0.75. Previous Next 1.7 News and Social Media Coverage News SentimentMarker Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Marker Therapeutics this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.10% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Marker Therapeutics are expected to remain at ($1.28) per share in the coming year.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Marker Therapeutics Stock (NASDAQ:MRKR)Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.Read More MRKR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRKR Stock News HeadlinesMay 2, 2024 | uk.investing.comMarker Therapeutics stock gets Buy from Ladenburg citing CAR-T therapy potentialMay 2, 2024 | benzinga.comMarker Therapeutics Stock (NASDAQ:MRKR), Analyst Ratings, Price Targets, PredictionsMay 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 1, 2024 | msn.comLadenburg Thalmann Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationMay 1, 2024 | americanbankingnews.comMarker Therapeutics (NASDAQ:MRKR) Receives New Coverage from Analysts at LADENBURG THALM/SH SHApril 30, 2024 | msn.comMile Marker 158 Dockside - Orange Beach, ALApril 27, 2024 | msn.com‘Useful way of marking history’: National Historic Marker Day asks residents to clean off local signsApril 27, 2024 | msn.com'Useful way of marking history': National Historic Marker Day asks residents to clean off local signsMay 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 10, 2024 | investing.comMarker Therapeutics Inc (MRKR)April 9, 2024 | msn.comPutnam Marker Honoring Warner Sisters Restored At Foundry Point ParkApril 8, 2024 | globenewswire.comPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic MalignanciesApril 3, 2024 | finance.yahoo.comGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular DiseasesMarch 26, 2024 | msn.comMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31MMarch 25, 2024 | globenewswire.comMarker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsMarch 22, 2024 | globenewswire.comMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 22, 2024 | msn.comJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party LeaderMarch 14, 2024 | finance.yahoo.comGlobal Marker Pens Market Projected to Reach $492.3 Million by 2030, Driven by a Robust CAGR of 5.2%March 13, 2024 | msn.comEliminate Marker Stains From Brick Surfaces With A Handy Hydrogen Peroxide TrickMarch 12, 2024 | finance.yahoo.comNimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of DirectorsFebruary 16, 2024 | usatoday.comLegislators: Why are women overlooked for Florida's Historical Marker Program?February 3, 2024 | msn.comEXPO Low Odor Dry Erase Marker Starter Set, Now 29% OffJanuary 22, 2024 | finance.yahoo.comMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601December 21, 2023 | finance.yahoo.comMarker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”December 12, 2023 | msn.comPSTX, MRKR and GPRO among pre-market losersDecember 11, 2023 | marketwatch.comMarker Therapeutics Shares Rise on Positive MT-601 UpdateDecember 11, 2023 | finance.yahoo.comMarker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseSee More Headlines Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/05/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees8Year Founded2018Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+160.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net Margins-142.62% Pretax Margin-424.10% Return on Equity-39.89% Return on Assets-25.45% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$3.31 million Price / Sales11.36 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book2.67Miscellaneous Outstanding Shares8,910,000Free Float6,765,000Market Cap$37.60 million OptionableNot Optionable Beta1.54 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Juan F. Vera M.D. (Age 43)Co-Founder, CEO, President, Treasurer & Director Comp: $529.12kMs. Elizabeth DonnellyDirector of AdministrationMr. Edmund CheungVice President of Human ResourcesDr. Nadia Agopyan Ph.D.Senior Vice President of Regulatory AffairsDr. Monic Stuart M.D.Chief Medical OfficerPatricia AllisonHead of Clinical OperationsMr. Michael J. Loiacono (Age 58)Secretary Comp: $287.98kDr. Robert Z. Florkiewicz Sr.Senior Director of Molecular Biology & VirologyMore ExecutivesKey CompetitorsSatsuma PharmaceuticalsNASDAQ:STSAEyenoviaNASDAQ:EYENVYNE TherapeuticsNASDAQ:VYNEAcurx PharmaceuticalsNASDAQ:ACXPBriaCell TherapeuticsNASDAQ:BCTXView All Competitors MRKR Stock Analysis - Frequently Asked Questions Should I buy or sell Marker Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MRKR shares. View MRKR analyst ratings or view top-rated stocks. What is Marker Therapeutics' stock price target for 2024? 1 brokers have issued twelve-month price objectives for Marker Therapeutics' stock. Their MRKR share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 160.7% from the stock's current price. View analysts price targets for MRKR or view top-rated stocks among Wall Street analysts. How have MRKR shares performed in 2024? Marker Therapeutics' stock was trading at $5.50 on January 1st, 2024. Since then, MRKR stock has decreased by 23.3% and is now trading at $4.22. View the best growth stocks for 2024 here. Are investors shorting Marker Therapeutics? Marker Therapeutics saw a drop in short interest in April. As of April 15th, there was short interest totaling 64,400 shares, a drop of 40.3% from the March 31st total of 107,900 shares. Based on an average daily volume of 18,700 shares, the short-interest ratio is presently 3.4 days. Approximately 1.0% of the shares of the stock are short sold. View Marker Therapeutics' Short Interest. When is Marker Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our MRKR earnings forecast. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 39.89% and a negative net margin of 142.62%. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS). How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRKR) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.